Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12750162 | 0.84 | PTGS2 (0.57) | IRAK4PTGS2MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL7410139 | 0.80 | MTNR1A (0.55) | PTGS2MTNR1AMTNR1BALDH1A1 | |
| Alcohol SCHEMBL9175412 | 0.76 | HTR7 (0.53) | PTGS2MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL9193406 | 0.75 | IRAK4 (0.46) | IRAK4TLR8NPSR1ALDH1A1ACHE | |
| SCHEMBL9035382 | 0.74 | IRAK4 (0.44) | IRAK4TLR8NPSR1ALDH1A1ACHE | |
| SCHEMBL1471497 | 0.73 | RAB9A (0.52) | ALDH1A1 | |
| SCHEMBL21415470 | 0.72 | IRAK4 (0.43) | IRAK4TLR8NPSR1ALDH1A1ACHE | |
| SCHEMBL14403060 | 0.70 | IRAK4 (0.39) | IRAK4TLR8NPSR1ALDH1A1ACHE | |
| SCHEMBL7410828 | 0.70 | HTR7 (0.47) | ACHE | |
| SCHEMBL29591819 | 0.70 | ALDH1A1 (0.57) | IRAK4TLR8NPSR1ALDH1A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915420-B2 | Aryl piperidine amides | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-29 | — | — | US | disclosed |
| US-20080009521-A1 | Aryl Piperidine Amides | HUANG CHARLES Q | 2008-01-10 | — | — | US | disclosed |
| US-7276610-B2 | Aryl piperidine amides | JANSSEN PHARACEUTICA, NV (BE) | 2007-10-02 | — | — | US | disclosed |
| EP-1660472-A1 | ARYL PIPERIDINE AMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005021525-A1 | ARYL PIPERIDINE AMIDES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-10 | — | — | WO | disclosed |
| US-20050049239-A1 | Aryl piperidine amides | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009521-A1 | Aryl Piperidine Amides | BDNF, NTRK2, OPRL1 | IRAK4 575/4885PTGS2 1038/4885CSNK2A1 2490/4885 |
| US-20050049239-A1 | Aryl piperidine amides | BDNF, NTRK2, OPRL1 | IRAK4 575/4885PTGS2 1038/4885CSNK2A1 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.